Core Insights - Micron Group has made significant progress in the field of intelligent neural regulation, with its subsidiary, Shanghai Micron Shanyi Medical Technology Co., successfully completing the first pre-market clinical study for the Einstein Deep Brain Stimulation (DBS) system [2][3] - The DBS system has shown promising results in early clinical trials, with all patients experiencing significant improvements in motor skills and quality of life, and no serious adverse reactions reported within a year [2][3] Group 1: Clinical Development - The first pre-market clinical study was led by Professors Sun Bomin and Wang Wei, with the first patient being a 50-year-old woman suffering from Parkinson's disease for four years [2] - The surgery involved precise three-dimensional localization based on MRI imaging, and the patient’s vital signs remained stable post-operation [2] Group 2: Market Potential - According to the "China Parkinson's Disease Report 2025," there are over 5 million Parkinson's disease patients in China, indicating a substantial market for DBS technology [3] - DBS technology is highlighted for its advantages, including non-destructive brain tissue treatment, reversibility, and adjustability, making it a viable option for patients with advanced Parkinson's disease where medication is less effective [3] Group 3: Strategic Implications - The successful implantation of the DBS system represents a breakthrough in China's high-end medical equipment innovation, with potential benefits for patients with neurological and psychiatric disorders [3] - The Einstein DBS system is not only aimed at treating Parkinson's disease but also serves as a scalable neural regulation technology platform for expanding treatment indications [3] - The success of the DBS product's first clinical trial validates the full-chain capabilities from research and development to clinical application, supporting the acceleration of future pipeline projects [3]
微创集团智能化神经调控领域布局取得新进展